A Phase 4 interventional study of B55R1 and B55R2 and B55R1 and placebo for B55R2 in Non-Proliferative Diabetic Retinopathy, sponsored by AJU Pharm Co., Ltd.. Completed at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by AJU Pharm Co., Ltd. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Diabetic Retinopathy with a site in Korea, Republic of — 2 open to participants now, 4 under way, none of them phase 3. Diabetic Retinopathy · Korea, Republic of.
Among the 14 studies in Diabetic Retinopathy with a site in Korea, Republic of, this one is the 5th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2022, is one of 4 in phase 4, and was the 12th registered.
783 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.
Browse Diabetic Retinopathy studies →2 of the 14 studies in Diabetic Retinopathy with a site in Korea, Republic of are open now. Recruiting first, the newest first:
VUNO Inc. · Sites in Korea, Republic of
Ages 19+
Kyungpook National University Hospital · Sites in Korea, Republic of
Ages 20–80 · Healthy volunteers
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 53 is below the median of 80 across 482 interventional studies indexed under Diabetic Retinopathy.
Median enrollment 49 across the 11 interventional studies, 206 across the 3 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 14 have an industry lead sponsor. The 10 most frequent:
AJU Pharm Co., Ltd. is the lead sponsor of 21 studies on the registry; 7 are open to participants now.
AJU Pharm Co., Ltd. has 1 study filed under Diabetic Retinopathy — fewer than ten, so there is no comparison to draw.
2 of the studies in Diabetic Retinopathy with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06770933Vantage Biosciences LtdA Study to Evaluate the Efficacy and Safety of Orally Administered VX-01 | 2027-07 |
| NCT07378956VUNO Inc.Clinical Efficacy of Implementing an AI-SaMD for Funduscopy Analysis in Patients With Diabetes Mellitus | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Diabetic Retinopathy with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is planned to evaluate the efficacy and safety of combination therapy with B55R1 and B55R2 compared to B55R1 monotherapy in patients with non-proliferative diabetic retinopathy (NPDR).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with the following ocular diseases or surgical procedures:
- Visual field defects, media opacity and ocular diseases other than diabetic retinopathywhich the investigator determines may affect the evaluation.
Patients with a history of within the past 5 years from the time of screening. However, the following are eligible for clinical trial participation:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
orally twice daily
Drug: B55R1 and B55R2
orally twice daily
Drug: B55R1 and placebo for B55R2
After Randomization(Week 0), Participants will be administered with the drug, 2 times in a day, until end of trial(Week 24).
After Randomization(Week 0), Participants will be administered with the drug, 2 times in a day, until end of trial(Week 24).
The proportion of subjects achieving a ≥1-step improvement in hard exudate grade at Week 24
The proportion of subjects achieving a ≥1-step improvement in hard exudate grade at Week 24
Time frame: Week 24
Changes in CMT as measured by OCT at Week 4, 12 and 24
Changes in CMT as measured by OCT at Week 4, 12 and 24
Time frame: Week 4, 12 and 24
The proportion of subjects achieving a ≥1-step improvement in hard exudate grade at Week 4 and 12
The proportion of subjects achieving a ≥1-step improvement in hard exudate grade at Week 4 and 12
Time frame: Week 4 and 12
Ran from Apr 2022 to primary completion in Aug 2023, 15 months.
Of 32 phase 4 interventional studies under Diabetic Retinopathy, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.